A Phase 3 interventional study of Abatacept and Placebo in Sjogrens Disease, sponsored by Bristol-Myers Squibb. Completed at 71 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-10.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy of abatacept compared to placebo in patients with Sjögren's Syndrome.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
Biological: Abatacept
Placebo for Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
Biological: Abatacept · Other: Placebo
Also known as: Orencia, Bristol-Myers Squibb (BMS)-188667
Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI)
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity (DA), Low = Low DA, Moderate = Moderate DA, High = High DA) Overall score, which can range from 0 to 123, a higher score indicates more disease activity
Time frame: Day 169
Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Inde (ESSPRI)
The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.
Time frame: Day 169
Change From Baseline in the Stimulated Whole Salivary Flow
The mean change from baseline in the stimulated whole salivary flow at Day 169
Time frame: Day 169
Change From Baseline of DAS28-C-reactive Peptide (CRP): In The Full Population
The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline of DAS28-CRP: Tender Swollen Joint Count of at Least 3
The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline of DAS28-CRP: Tender Swollen Joints Count Less Than 3
The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in the Joint Component of DAS28-CRP: In the Full Population
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in the CRP Component of DAS28-CRP: In the Full Population
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: In the Full Population
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in the Joint Component of DAS28-CRP: Tender Swollen Joints of at Least 3
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in the CRP Component of DAS28-CRP: Tender Swollen Joints of at Least 3
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: Tender Swollen Joints of at Least 3
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in the Joint Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in the CRP Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in the Assessment of Disease Activity Component of DAS28-CRP: Tender Swollen Joint Count Less Than 3
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Participants Who Achieve Minimally Clinically Important Change in ESSDAI in at Least 3 Points
Proportion of participants who achieve a minimally clinically important change (of at least 3 points) in the ESSDAI at all measured time points up to Day 169.
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Participants Who Achieve Minimally Clinically Important Change in ESSDAI in at Least 5 Points
Proportion of participants who achieve a minimally clinically important change (of at least 5 points) in the ESSDAI at all measured time points up to Day 169.
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Participants Who Achieve Minimally Clinically Important Change in ESSPRI in at Least 1 Point
Proportion of participants who achieve a minimally clinically important change (of at least 1 point) in the ESSPRI at all measured time points up to Day 169.
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline at All Measured Time Points in the ESSDAI
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity (DA), Low = Low DA, Moderate = Moderate DA, High = High DA) Overall score, which can range from 0 to 123, a higher score indicates more disease activity
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline at All Measured Time Points in the ESSPRI
The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in Components of ESSDAI
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score for activity level) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity, Low = Low Disease Activity, Moderate = Moderate Disease Activity, High = High Disease Activity)
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141 and Day 169
Change From Baseline in ESSPRI Components
The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.
Time frame: Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Change From Baseline in Schirmer's Test
The Mean change from baseline in Schirmer's Test at all measured time points up to day 169 The length in millimeters that the strip wets during the 5 minute test period for each eye. Collection is done separately for each eye.
Time frame: Day 85, Day 169
Change From Baseline in the Ocular Staining Score (OSS)
The Mean change from baseline in OSS at all measured time points up to day 169 Score of 0 = No Staining Score of 12 = diffuse staining The total score will be calculated as the sum of the score for these parameters for each eye. Medial Nasal Bulbar Conjunctiva (MNBC) \[score scale: 0 - 3\], Corneal (CORN) Staining of Punctate Epithelial Erosions (PEE) \[score scale: 0 - 3\], Lateral Temporal Bulbar Conjunctiva (LTBC) \[score scale: 0 - 3\], Patches of Confluent Staining (CONF) \[score scale: 0 - 1\], PEE observed in the pupil region, i.e. central 4mm diameter portion of the cornea (PUPL) \[score scale: 0 - 1\], one of more filaments seen anywhere on the cornea (FILA) \[score scale: 0 - 1\]
Time frame: Day 85, Day 169
Change From Baseline in Tear Break-up Time
The Mean change from baseline in Tear Break-up Time at all measured time points up to day 169 The CRF collects the time in seconds to first appearance of a random dry spot on the corneal surface for 3 repetitions in each eye. The average time will calculated for each eye averaging the 3 measurements for each eye separately. In case only 2 measurements are available, the average of the 2 measurements will be calculated. In case there is only 1 measurement, that measurement will be used for the analysis.
Time frame: Day 85, Day 169
Change From Baseline in Unstimulated Salivary Flow
The mean change from baseline in unstimulated whole salivary flow at all measured time points up to Day 169.
Time frame: Day 85, Day 169
Change From Baseline in Stimulated Salivary Flow
The mean change from baseline in Stimulated whole salivary flow at all measured time points up to Day 169.
Time frame: Day 85, Day 169
Change From Baseline in Numeric Rating Scale for Mouth Dryness
The mean change from baseline in participant symptoms using the Numeric Rating Scale (NRS) for mouth dryness at all measured time points up to Day 169. The oral and ocular dryness are each assessed by the patients with numeric rating scales from 0 to 10 with 0 representing no dryness and 10 representing maximal dryness
Time frame: Day 1, 29, 57, 85, 113, 141, 169
Change From Baseline in Numeric Rating Scale for Eye Dryness
The mean change from baseline in patient symptoms using the Numeric Rating Scale (NRS) for eye dryness at all measured time points up to Day 169. The oral and ocular dryness are each assessed by the patients with numeric rating scales from 0 to 10 with 0 representing no dryness and 10 representing maximal dryness
Time frame: Day 1, 29, 57, 85, 113, 141, 169
Change From Baseline in Participant Assessment of Disease Activity
The participant global assessment of disease activity are assessed with visual analog scales. The participant marks a vertical line through a horizontal line, where the beginning of the horizontal line represents the best situation, and the end of the horizontal line represents the very worst situation. The CRF collects the distance in millimeters from the start of the scale that is marked as well as the length of the scale in millimeters. In cases that the length of the scale is in less or more than 100 millimeters, then the participants measurement will be rescaled to the equivalent of 100 millimeters using the formula below: Rescale Measurement in mm = (measurement as reported on CRF in mm/length of the line on CRF in mm) \* 100mm A negative score = participant assessment of disease activity has improved A positive score = participant assessment of disease activity has worsened
Time frame: Day 29, 57, 85, 113, 141, 169
Change From Baseline in Physician Global Assessment of Disease Activity
The physician global assessment of disease activity are assessed with visual analog scales. The physician marks a vertical line through a horizontal line, where the beginning of the horizontal line represents the best situation, and the end of the horizontal line represents the very worst situation. The CRF collects the distance in millimeters from the start of the scale that is marked as well as the length of the scale in millimeters. In cases that the length of the scale is in less or more than 100 millimeters, then the participants measurement will be rescaled to the equivalent of 100 millimeters using the formula below: Rescale Measurement in mm = (measurement as reported on CRF in mm/length of the line on CRF in mm) \* 100mm A negative score = physician assessment of disease activity has improved A positive score = physician assessment of disease activity has worsened
Time frame: Day 29, 57, 85, 113, 141, 169
Change From Baseline in Patient Fatigue
The mean change from baseline in patient fatigue using Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue assessment of disease activity at all measured time points up to Day 169. PROMIS Fatigue instruments 10 Questions ranging from a score 0 to 40. Sum of the values gives you the raw sum. The raw is inputted into this formula to give you the raw score: Raw Score = (Raw sum\*number of items on the short form)/(Number of items that were actually answered) Raw score is translated to a T-Score using a table. T-Score is used as the final score. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. The standardized T-score is reported as the final score for each participant. A negative T Score = Better Prognosis A positive T Score = Worse prognosis
Time frame: Day 29, 57, 85, 113, 141, 169
Change From Baseline in Female Sexual Function Using the Female Sexual Function Index (FSFI)
For the FSFI, is a 19 item instrument used for assessing key dimensions of female sexual function over the past 4 weeks with 6 domains being analyzed. The specific domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) analyzed in the FSFI are scored on a scale ranging from 0 to 5, with higher scores indicating better performance. Domain scores are calculated by summing the scores of the individual questions that make up the domain and multiplying the sum by the factor in the table below. The full scale score is the sum of the six domain scores. Full Scale Score range: 2.0(minimum score) - 36.0 (maximum score) Negative Score = Reduced functioning Positive Score = Improved functioning
Time frame: Day 85, Day 169
Change From Baseline in 36-item Short Form Health Survey (SF-36)
The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement
Time frame: Day 85, Day 169
Geometric Mean of Trough Concentration (Cmin) of Abatacept
Geometric mean of trough concentration (Cmin) of abatacept at all measured time points.
Time frame: Day 29, 85, 113, 141, 169
Percentage of Participants With a Positive Antibody Response
Percentage of participants with at least one positive immunogenicity response up to Day 169 and during 3 months follow up (for participants who discontinue during the 6-months double-blind).
Time frame: Day 85 db, day 169 db, post treatment day 85
Summary of Adverse Events: Double Blind Period
Percentage of participants with adverse events, deaths, serious adverse events and adverse events leading to discontinuation
Time frame: Day 1 up to first dose of Open Label Treatment Period (OLTP) abatacept or up to 56 post last dose in double -blind for those not in OL.
Laboratory Marked Abnormalities: Double Blind Period
Laboratory values meeting the marked abnormality criteria
Time frame: Day 1 up to first dose of OL abatacept or up to 56 post last dose in double -blind for those not in OL.
Percentage of Participants With a Positive Antibody Response in the Cumulative Abatacept Period
Percentage of participants with at least one positive immunogenicity response On Day 365 (end of Open label treatment period) and day 85 post open label follow up period.
Time frame: Day 365, post open label treatment day 85
Summary of Adverse Events: Cumulative Abatacept Period
Percentage of participants with adverse events, deaths, serious adverse events and adverse events leading to discontinuation
Time frame: Day 365 and 3 months of follow up approximately 450 Days
Laboratory Marked Abnormalities: Cumulative Abatacept Period
Laboratory values meeting the marked abnormality criteria
Time frame: Day 365 and 3 months of follow up approximately 450 Days
| Milestone | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Started | 92 | 95 |
| Completed | 81 | 87 |
| Not completed | 11 | 8 |
| Withdrew: Participant no longer meets criteria | 2 | 0 |
| Withdrew: Poor/non-compliance | 1 | 0 |
| Withdrew: Participant withdrew consent | 5 | 1 |
| Withdrew: Request to discontinue treatment | 1 | 2 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Lack of efficacy | 0 | 3 |
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity (DA), Low = Low DA, Moderate = Moderate DA, High = High DA) Overall score, which can range from 0 to 123, a higher score indicates more disease activity
| Score on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Change From Baseline in EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) | -3.2 (-4.6 to -1.9) | -3.7 (-5.0 to -2.4) |
The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.
| Score on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Change From Baseline in EULAR Sjogren's Syndrome Patient Reported Inde (ESSPRI) | -1.26 (-1.88 to -0.64) | -1.52 (-2.12 to -0.93) |
The mean change from baseline in the stimulated whole salivary flow at Day 169
| mL/min | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Change From Baseline in the Stimulated Whole Salivary Flow | 0.057 (-0.115 to 0.230) | 0.108 (-0.060 to 0.276) |
The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity
| Scores on a scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | -0.4 (-0.6 to -0.2) | -0.4 (-0.6 to -0.2) |
| Day 57 | -0.6 (-0.8 to -0.4) | -0.7 (-0.9 to -0.4) |
| Day 85 | -0.8 (-1.0 to -0.6) | -0.8 (-1.1 to -0.6) |
| Day 113 | -0.8 (-1.0 to -0.5) | -1.0 (-1.2 to -0.7) |
| Day 141 | -0.8 (-1.0 to -0.5) | -1.0 (-1.3 to -0.8) |
| Day 169 | -0.9 (-1.1 to -0.6) | -1.1 (-1.4 to -0.9) |
The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity
| Scores on a scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | -0.5 (-0.8 to -0.2) | -0.6 (-0.9 to -0.3) |
| Day 57 | -0.9 (-1.2 to -0.5) | -1.0 (-1.3 to -0.6) |
| Day 85 | -1.1 (-1.5 to -0.7) | -1.2 (-1.5 to -0.8) |
| Day 113 | -1.1 (-1.4 to -0.7) | -1.4 (-1.7 to -1.0) |
| Day 141 | -1.2 (-1.5 to -0.8) | -1.5 (-1.8 to -1.1) |
| Day 169 | -1.3 (-1.7 to -0.9) | -1.5 (-1.9 to -1.2) |
The disease activity score DAS28-CRP is a continuous variable which is a composite of 4 variables: the 28 tender joint count (tender28), the 28 swollen joint count (swollen28), CRP and participant assessment of disease activity measure on a visual analogue scale (VAS) of 100mm. DAS28-CRP = 0.56 \* sqrt(tender28) + 0.28 \* sqrt(swollen28) + 0.36 \* ln(hsCRP+1) + 0.014 \* VAS + 0.96. (sqrt = Square root, ln = natural log) Positive Scores = Increased Disease Activity Negative Scores = Reduced Disease Activity
| Scores on a scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | -0.3 (-0.6 to 0.0) | -0.2 (-0.6 to 0.1) |
| Day 57 | -0.2 (-0.5 to 0.1) | -0.2 (-0.5 to 0.1) |
| Day 85 | -0.4 (-0.6 to -0.1) | -0.4 (-0.7 to -0.1) |
| Day 113 | -0.3 (-0.6 to -0.0) | -0.3 (-0.6 to -0.1) |
| Day 141 | -0.2 (-0.5 to 0.1) | -0.4 (-0.7 to -0.0) |
| Day 169 | -0.3 (-0.5 to -0.0) | -0.5 (-0.7 to -0.2) |
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted
| Joint Count | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 - Tender Joint | -1.7 (-2.8 to -0.7) | -1.9 (-2.9 to -0.8) |
| Day 29 - Swollen Joint | -0.5 (-1.0 to 0.1) | -0.6 (-1.1 to -0.1) |
| Day 57 - Tender Joint | -2.6 (-3.7 to -1.5) | -2.9 (-4.0 to -1.9) |
| Day 57 - Swollen Joint | -1.0 (-1.6 to -0.3) | -1.0 (-1.6 to -0.4) |
| Day 85 - Tender Joint | -2.9 (-4.1 to -1.7) | -3.4 (-4.6 to -2.2) |
| Day 85 - Swollen Joint | -1.4 (-2.0 to -0.8) | -1.4 (-2.0 to -0.9) |
| Day 113 - Tender Joint | -3.1 (-4.2 to -2.0) | -3.9 (-5.0 to -2.8) |
| Day 113 - Swollen Joint | -1.5 (-2.0 to -1.1) | -1.9 (-2.3 to -1.4) |
| Day 141 - Tender Joint | -3.6 (-4.7 to -2.5) | -4.1 (-5.2 to -3.0) |
| Day 141 - Swollen Joint | -1.4 (-1.9 to -0.8) | -1.8 (-2.4 to -1.3) |
| Day 169 - Tender Joint | -2.9 (-4.0 to -1.7) | -4.4 (-5.6 to -3.3) |
| Day 169 - Swollen Joint | -1.4 (-1.9 to -0.8) | -2.0 (-2.6 to -1.5) |
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP
| mg/L | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 - CRP | 0.3 (-1.4 to 2.0) | 0.6 (-1.0 to 2.3) |
| Day 57 - CRP | -0.1 (-2.1 to 1.8) | 1.8 (-0.1 to 3.6) |
| Day 85 - CRP | -0.2 (-5.0 to 4.5) | 3.0 (-1.6 to 7.6) |
| Day 113 - CRP | 1.6 (-0.8 to 4.1) | 0.3 (-2.1 to 2.6) |
| Day 141 - CRP | 3.5 (-1.7 to 8.8) | -0.2 (-5.2 to 4.7) |
| Day 169 - CRP | -0.2 (-1.8 to 1.3) | 0.0 (-1.5 to 1.5) |
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity
| Scores on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 - Assessment of Disease Activity | -4.0 (-9.8 to 1.7) | -7.1 (-12.7 to -1.4) |
| Day 57 - Assessment of Disease Activity | -7.5 (-13.4 to -1.7) | -6.3 (-11.9 to -0.6) |
| Day 85 - Assessment of Disease Activity | -10.4 (-16.3 to -4.4) | -10.2 (-16.0 to -4.4) |
| Day 113 - Assessment of Disease Activity | -8.0 (-14.0 to -2.0) | -9.7 (-15.5 to -3.9) |
| Day 141 - Assessment of Disease Activity | -5.1 (-11.0 to 0.8) | -11.0 (-16.7 to -5.3) |
| Day 169 - Assessment of Disease Activity | -10.1 (-16.1 to -4.0) | -9.0 (-14.8 to -3.1) |
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted
| Joint Count | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 - Tender Joint | -2.8 (-4.5 to -1.0) | -3.0 (-4.7 to -1.3) |
| Day 29 - Swollen Joint | -0.7 (-1.5 to 0.2) | -0.9 (-1.7 to -0.1) |
| Day 57 - Tender Joint | -4.1 (-5.9 to -2.3) | -4.8 (-6.5 to -3.0) |
| Day 57 - Swollen Joint | -1.5 (-2.6 to -0.5) | -1.6 (-2.6 to -0.5) |
| Day 85 - Tender Joint | -4.4 (-6.3 to -2.4) | -5.4 (-7.2 to -3.6) |
| Day 85 - Swollen Joint | -2.1 (-3.1 to -1.1) | -2.2 (-3.2 to -1.3) |
| Day 113 - Tender Joint | -4.8 (-6.6 to -2.9) | -6.0 (-7.7 to -4.2) |
| Day 113 - Swollen Joint | -2.3 (-3.2 to -1.5) | -2.9 (-3.7 to -2.2) |
| Day 141 - Tender Joint | -5.7 (-7.5 to -3.8) | -6.4 (-8.2 to -4.7) |
| Day 141 - Swollen Joint | -2.2 (-3.1 to -1.3) | -3.0 (-3.8 to -2.1) |
| Day 169 - Tender Joint | -4.6 (-6.5 to -2.7) | -6.7 (-8.5 to -4.9) |
| Day 169 - Swollen Joint | -2.2 (-3.1 to -1.3) | -3.1 (-4.0 to -2.3) |
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP
| mg/L | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 - CRP | -1.5 (-3.7 to 0.7) | -0.7 (-2.8 to 1.4) |
| Day 57 - CRP | -1.3 (-4.3 to 1.7) | 1.3 (-1.5 to 4.0) |
| Day 85 - CRP | -2.2 (-9.8 to 5.5) | 3.8 (-3.4 to 11.0) |
| Day 113 - CRP | 1.2 (-2.7 to 5.1) | -0.4 (-4.0 to 3.2) |
| Day 141 - CRP | 4.5 (-4.0 to 12.9) | -1.4 (-9.0 to 6.3) |
| Day 169 - CRP | -1.4 (-3.9 to 1.1) | -0.7 (-3.0 to 1.6) |
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity
| Score on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 - Assessment of Disease Activity | 0.6 (-6.9 to 8.1) | -3.5 (-10.7 to 3.7) |
| Day 57 - Assessment of Disease Activity | -3.5 (-11.5 to 4.5) | -6.5 (-14.0 to 1.1) |
| Day 85 - Assessment of Disease Activity | -7.5 (-15.5 to 0.4) | -7.7 (-15.3 to -0.1) |
| Day 113 - Assessment of Disease Activity | -6.6 (-14.4 to 1.3) | -9.1 (-16.5 to -1.6) |
| Day 141 - Assessment of Disease Activity | -1.2 (-9.0 to 6.7) | -8.1 (-15.5 to -0.7) |
| Day 169 - Assessment of Disease Activity | -6.7 (-14.9 to 1.5) | -7.8 (-15.5 to -0.0) |
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Tender Joint: Count 1-28 Swollen Joint: Count 1-28 Negative Scores = Reduced number of joints impacted Positive Scores = Increased number of joints impacted
| Joint Count | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 - Tender Joint | -0.1 (-0.9 to 0.6) | -0.2 (-0.9 to 0.6) |
| Day 29 - Swollen Joint | 0.1 (-0.2 to 0.3) | 0.1 (-0.2 to 0.4) |
| Day 57 - Tender Joint | -0.2 (-0.9 to 0.6) | 0.1 (-0.6 to 0.9) |
| Day 57 - Swollen Joint | 0.2 (-0.1 to 0.4) | 0.0 (-0.2 to 0.3) |
| Day 85 - Tender Joint | -0.5 (-1.3 to 0.2) | 0.1 (-0.7 to 0.8) |
| Day 85 - Swollen Joint | -0.0 (-0.3 to 0.2) | 0.1 (-0.2 to 0.4) |
| Day 113 - Tender Joint | -0.4 (-1.2 to 0.3) | -0.5 (-1.3 to 0.3) |
| Day 113 - Swollen Joint | 0.0 (-0.3 to 0.3) | 0.1 (-0.2 to 0.4) |
| Day 141 - Tender Joint | -0.2 (-1.0 to 0.6) | -0.2 (-1.0 to 0.6) |
| Day 141 - Swollen Joint | 0.2 (-0.1 to 0.5) | 0.3 (0.0 to 0.6) |
| Day 169 - Tender Joint | -0.1 (-0.9 to 0.7) | -0.7 (-1.4 to 0.1) |
| Day 169 - Swollen Joint | 0.2 (-0.1 to 0.5) | -0.0 (-0.3 to 0.2) |
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. CRP: measured lab value Positive Number = Increased level of CRP Negative Number = Reduced Level of CRP
| mg/L | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 - CRP | 2.1 (-0.8 to 4.9) | 1.8 (-1.2 to 4.7) |
| Day 57 - CRP | 0.5 (-2.3 to 3.4) | 1.0 (-1.9 to 3.9) |
| Day 85 - CRP | 1.4 (-1.5 to 4.3) | 0.1 (-2.8 to 3.1) |
| Day 113 - CRP | 1.3 (-1.6 to 4.1) | 0.1 (-2.8 to 3.1) |
| Day 141 - CRP | 0.7 (-2.2 to 3.6) | 0.8 (-2.1 to 3.8) |
| Day 169 - CRP | 0.2 (-2.7 to 3.1) | 0.2 (-2.8 to 3.1) |
The mean change from baseline at all measured time points up to Day 169 in the individual components of DAS28-CRP. Assesment of Disease Activity: 0-100 scale \[100=Most severe\] Positive Numbers = Increased Disease Activity Negative Numbers = Decreased Diseased activity
| Scores on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 - Assessment of Disease Activity | -10.3 (-19.3 to -1.4) | -11.8 (-21.3 to -2.3) |
| Day 57 - Assessment of Disease Activity | -12.4 (-21.4 to -3.4) | -4.8 (-14.3 to 4.7) |
| Day 85 - Assessment of Disease Activity | -14.0 (-23.0 to -5.0) | -13.5 (-23.0 to -4.0) |
| Day 113 - Assessment of Disease Activity | -9.1 (-18.1 to -0.0) | -11.1 (-20.6 to -1.5) |
| Day 141 - Assessment of Disease Activity | -10.6 (-19.8 to -1.5) | -15.3 (-24.8 to -5.7) |
| Day 169 - Assessment of Disease Activity | -13.8 (-23.0 to -4.6) | -10.9 (-20.5 to -1.4) |
Proportion of participants who achieve a minimally clinically important change (of at least 3 points) in the ESSDAI at all measured time points up to Day 169.
| Percentage | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | 37 (27.1 to 47.7) | 34.7 (25.3 to 45.2) |
| Day 57 | 37 (27.1 to 47.7) | 44.2 (34.0 to 54.8) |
| Day 85 | 48.9 (38.3 to 59.6) | 50.5 (40.1 to 60.9) |
| Day 113 | 55.4 (44.7 to 65.8) | 50.5 (40.1 to 60.9) |
| Day 141 | 51.1 (40.4 to 61.7) | 56.8 (46.3 to 67.0) |
| Day 169 | 55.4 (44.7 to 65.8) | 57.9 (47.3 to 68.0) |
Proportion of participants who achieve a minimally clinically important change (of at least 5 points) in the ESSDAI at all measured time points up to Day 169.
| Percentage | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | 19.6 (12.0 to 29.1) | 13.7 (7.5 to 22.3) |
| Day 57 | 26.1 (17.5 to 36.3) | 24.2 (16.0 to 34.1) |
| Day 85 | 34.8 (25.1 to 45.4) | 32.6 (23.4 to 43.0) |
| Day 113 | 37.0 (27.1 to 47.7) | 36.8 (27.2 to 47.4) |
| Day 141 | 37.0 (27.1 to 47.7) | 36.8 (31.1 to 51.6) |
| Day 169 | 35.9 (26.1 to 46.5) | 46.3 (36.0 to 56.8) |
Proportion of participants who achieve a minimally clinically important change (of at least 1 point) in the ESSPRI at all measured time points up to Day 169.
| Percentage | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | 31.5 (22.2 to 42.0) | 38.9 (29.1 to 49.5) |
| Day 57 | 42.4 (32.1 to 53.1) | 47.4 (37.0 to 57.9) |
| Day 85 | 44.6 (34.2 to 55.3) | 55.8 (45.2 to 66.0) |
| Day 113 | 42.4 (32.1 to 53.1) | 52.6 (42.1 to 63.0) |
| Day 141 | 40.2 (30.1 to 51.0) | 54.7 (44.2 to 65.0) |
| Day 169 | 41.3 (31.1 to 52.1) | 52.6 (42.1 to 63.0) |
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity (DA), Low = Low DA, Moderate = Moderate DA, High = High DA) Overall score, which can range from 0 to 123, a higher score indicates more disease activity
| Percent Change from Baseline | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | -10.9 (-22.3 to 0.54) | -12.6 (-23.71 to -1.39) |
| Day 57 | -24.1 (-36.10 to -12.08) | -18.9 (-30.52 to -7.32) |
| Day 85 | -26.0 (-38.81 to -13.17) | -25.4 (-37.76 to -13.01) |
| Day 113 | -34.1 (-46.8 to -21.34) | -32.1 (-44.35 to -19.83) |
| Day 141 | -29.7 (-43.02 to -16.31) | -37.0 (-49.81 to -24.12) |
| Day 169 | -33.4 (-46.54 to -20.24) | -37.6 (-50.24 to -25.02) |
The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.
| Score on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | -0.32 (-0.79 to 0.16) | -0.54 (-1.00 to -0.08) |
| Day 57 | -0.81 (-1.32 to -0.31) | -0.82 (-1.31 to -0.33) |
| Day 85 | -0.83 (-1.34 to -0.32) | -1.20 (-1.70 to -0.70) |
| Day 113 | -0.79 (-1.32 to -0.26) | -1.37 (-1.88 to -0.86) |
| Day 141 | -0.87 (-1.40 to -0.35) | -1.32 (-1.83 to -0.81) |
| Day 169 | -1.03 (-1.55 to -0.50) | -1.30 (-1.80 to -0.79) |
The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) total score is calculated as the sum of scores for activity level for each domain. The EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) Scoring Algorithm. Domain: (Score for activity level) Constitutional: (No=0, Low=3, Moderate=6) Lymphadenopathy: (No=0, Low=4, Moderate=8, High=12) Glandular: (No=0, Low=2, Moderate=4) Articular: (No=0, Low=2, Moderate=4, High=6) Cutaneous: (No=0, Low=3, Moderate=6, High=9) Pulmonary: (No=0, Low=5, Moderate=10, High=15) Renal: (No=0, Low=5, Moderate=10, High=15) Muscular: (No=0, Low=6, Moderate=12, High=18) Peripheral Nervous System (PNS): (No=0, Low=5, Moderate=10, High=15) Central Nervous System (CNS): (No=0, Moderate=10, High=15) Haematological: (No=0, Low=2, Moderate=4, High=6) Biological: (No=0, Low=1, Moderate=2) (No = No Disease Activity, Low = Low Disease Activity, Moderate = Moderate Disease Activity, High = High Disease Activity)
| Score on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29: Constitutional | -0.3 (-0.4 to -0.1) | -0.4 (-0.5 to -0.2) |
| Day 29: Lymphadenopathy | -0.6 (-1.0 to -0.2) | -0.5 (-0.9 to -0.2) |
| Day 29: Glandular | -0.2 (-0.4 to 0.0) | -0.2 (-0.4 to 0.0) |
| Day 29: Articular | -0.4 (-0.8 to 0.0) | -0.3 (-0.7 to 0.1) |
| Day 29: Cutaneous | -0.3 (-0.6 to -0.0) | -0.2 (-0.5 to 0.1) |
| Day 29: Pulmonary | 0.0 (-0.3 to 0.3) | 0.1 (-0.2 to 0.4) |
| Day 29: Renal | -0.0 (-0.2 to 0.2) | -0.2 (-0.3 to 0.0) |
| Day 29: Muscular | -0.0 (-0.1 to 0.1) | -0.0 (-0.1 to 0.1) |
| Day 29: Peripheral Nervous System | -0.0 (-0.2 to 0.2) | 0.0 (-0.2 to 0.20) |
| Day 29: Haematogical | 0.2 (-0.0 to 0.4) | 0.1 (-0.1 to 0.4) |
| Day 29: Biological | 0.1 (-0.1 to 0.2) | 0.1 (-0.0 to 0.3) |
| Day 57: Constitutional | -0.2 (-0.4 to -0.0) | -0.3 (-0.5 to -0.1) |
| Day 57: Lymphadenopathy | -0.7 (-1.1 to -0.2) | -0.6 (-1.0 to -0.2) |
| Day 57: Glandular | -0.4 (-0.7 to -0.2) | -0.4 (-0.6 to -0.1) |
| Day 57: Articular | -0.7 (-1.1 to -0.3) | -0.8 (-1.2 to -0.4) |
| Day 57: Cutaneous | -0.3 (-0.6 to -0.0) | -0.2 (-0.5 to 0.1) |
| Day 57: Pulmonary | -0.0 (-0.3 to 0.3) | 0.2 (-0.1 to 0.5) |
| Day 57: Renal | -0.0 (-0.2 to 0.2) | -0.1 (-0.3 to 0.1) |
| Day 57: Muscular | -0.0 (-0.1 to 0.1) | -0.1 (-0.2 to -0.0) |
| Day 57: Peripheral Nervous System | -0.0 (-0.2 to 0.2) | 0.0 (-0.2 to 0.2) |
| Day 57: Haematological | 0.1 (-0.1 to 0.4) | 0.2 (-0.0 to 0.4) |
| Day 57: Biological | -0.1 (-0.2 to 0.1) | 0.0 (-0.1 to 0.2) |
| Day 85: Constitutional | -0.3 (-0.5 to -0.1) | -0.4 (-0.6 to -0.2) |
| Day 85: Lymphadenopathy | -0.7 (-1.1 to -0.3) | -0.8 (-1.2 to -0.4) |
| Day 85: Glandular | -0.4 (-0.6 to -0.1) | -0.5 (-0.7 to -0.2) |
| Day 85: Articular | -1.0 (-1.5 to -0.6) | -1.1 (-1.6 to -0.7) |
| Day 85: Cutaneous | -0.4 (-0.7 to -0.0) | -0.2 (-0.5 to 0.1) |
| Day 85: Pulmonary | 0.0 (-0.3 to 0.4) | 0.2 (-0.1 to 0.5) |
| Day 85: Renal | -0.1 (-0.3 to 0.1) | -0.1 (-0.3 to 0.1) |
| Day 85: Muscular | -0.1 (-0.2 to 0.0) | -0.0 (-0.1 to 0.1) |
| Day 85: Peripheral Nervous System | -0.0 (-0.2 to 0.2) | 0.0 (-0.2 to 0.2) |
| Day 85: Haematological | 0.1 (-0.1 to 0.3) | 0.2 (-0.1 to 0.4) |
| Day 85: Biological | 0.0 (-0.1 to 0.2) | 0.2 (0.0 to 0.3) |
| Day 113: Constitutional | -0.3 (-0.5 to -0.0) | -0.3 (-0.5 to -0.1) |
| Day 113: Lymphadenopathy | -0.8 (-1.2 to -0.4) | -0.9 (-1.3 to -0.5) |
| Day 113: Glandular | -0.5 (-0.7 to -0.3) | -0.5 (-0.8 to -0.3) |
| Day 113: Articular | -1.3 (-1.8 to -0.8) | -1.3 (-1.7 to -0.8) |
| Day 113: Cutaneous | -0.4 (-0.7 to -0.1) | -0.4 (-0.7 to -0.1) |
| Day 113: Pulmonary | 0.0 (-0.3 to 0.4) | 0.1 (-0.2 to 0.5) |
| Day 113: Renal | -0.1 (-0.3 to 0.1) | 0.0 (-0.2 to 0.2) |
| Day 113: Muscular | -0.0 (-0.1 to 0.1) | -0.1 (-0.2 to 0.0) |
| Day 113: Peripheral Nervous System | -0.0 (-0.2 to 0.2) | -0.0 (-0.2 to 0.1) |
| Day 113: Haematological | 0.1 (-0.2 to 0.3) | 0.2 (-0.0 to 0.4) |
| Day 113: Biological | -0.0 (-0.2 to 0.1) | 0.1 (-0.0 to 0.3) |
| Day 141: Constitutional | -0.2 (-0.4 to 0.0) | -0.4 (-0.6 to -0.2) |
| Day 141: Lymphadenopathy | -0.6 (-1.1 to -0.2) | -0.9 (-1.4 to -0.5) |
| Day 141: Glandular | -0.5 (-0.7 to -0.2) | -0.6 (-0.8 to -0.4) |
| Day 141: Articular | -1.2 (-1.7 to -0.8) | -1.4 (-1.9 to -1.0) |
| Day 141: Cutaneous | -0.4 (-0.7 to -0.1) | -0.5 (-0.8 to -0.3) |
| Day 141: Pulmonary | -0.0 (-0.4 to 0.3) | 0.1 (-0.2 to 0.4) |
| Day 141: Renal | -0.0 (-0.2 to 0.2) | -0.1 (-0.3 to 0.1) |
| Day 141: Muscular | -0.1 (-0.2 to 0.0) | -0.1 (-0.2 to 0.0) |
| Day 141: Peripheral Nervous System | -0.1 (-0.3 to 0.1) | -0.0 (-0.2 to 0.1) |
| Day 141: Haematological | 0.1 (-0.1 to 0.4) | 0.1 (-0.1 to 0.4) |
| Day 141: Biological | -0.0 (-0.2 to 0.1) | 0.1 (-0.0 to 0.2) |
| Day 169: Constitutional | -0.3 (-0.5 to -0.1) | -0.4 (-0.6 to -0.2) |
| Day 169: Lymphadenopathy | -0.9 (-1.3 to -0.5) | -1.1 (-1.4 to -0.7) |
| Day 169: Glandular | -0.4 (-0.6 to -0.1) | -0.5 (-0.8 to -0.3) |
| Day 169: Articular | -1.4 (-1.8 to -0.9) | -1.8 (-2.2 to -1.4) |
| Day 169: Cutaneous | -0.3 (-0.7 to 0.0) | -0.5 (-0.9 to -0.2) |
| Day 169: Pulmonary | -0.0 (-0.4 to 0.3) | 0.1 (-0.2 to 0.4) |
| Day 169: Renal | -0.0 (-0.2 to 0.2) | 0.0 (-0.2 to 0.2) |
| Day 169: Muscular | -0.0 (-0.1 to 0.1) | -0.1 (-0.2 to 0.0) |
| Day 169: Peripheral Nervous | -0.1 (-0.3 to 0.1) | -0.0 (-0.2 to 0.2) |
| Day 169: Haematological | 0.1 (-0.2 to 0.3) | 0.3 (0.1 to 0.5) |
| Day 169: Biological | 0.0 (-0.1 to 0.2) | 0.2 (0.0 to 0.3) |
The total score EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) is calculated as the mean of the 3 individual components. Total Score Range (0 = Best outcome and 10 = Worst Outcome) The scores for the ESSPRI individual components will be used as such reported by the participants and entered in the case report form (CRF), without any further calculations. It consists of 3 questions covering cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain. Each domain scored on scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable), and overall score is calculated as the mean of 3 individual domains.
| Score on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29: Dryness Score | -0.21 (-0.76 to 0.34) | -0.26 (-0.80 to 0.28) |
| Day 29: Fatigue Score | -0.57 (-1.18 to 0.03) | -1.01 (-1.60 to -0.42) |
| Day 29: Pain Score | -0.34 (-0.96 to 0.27) | -0.53 (-1.13 to 0.07) |
| Day 57: Dryness Score | -0.92 (-1.51 to -0.33) | -0.52 (-1.09 to 0.05) |
| Day 57: Fatigue Score | -1.09 (-1.70 to -0.48) | -1.22 (-1.81 to -0.63) |
| Day 57: Pain Score | -0.60 (-1.24 to 0.05) | -0.90 (-1.52 to -0.27) |
| Day 85: Dryness Score | -0.68 (-1.25 to -0.11) | -0.91 (-1.46 to -0.36) |
| Day 85: Fatigue Score | -1.27 (-1.91 to -0.63) | -1.56 (-2.18 to -0.94) |
| Day 85: Pain Score | -0.70 (-1.35 to -0.05) | -1.31 (-1.93 to -0.68) |
| Day 113: Dryness Score | -0.74 (-1.36 to -0.12) | -1.19 (-1.79 to -0.60) |
| Day 113: Fatigue Score | -1.02 (-1.65 to -0.39) | -1.76 (-2.37 to -1.15) |
| Day 113: Pain Score | -0.76 (-1.40 to -0.11) | -1.37 (-1.99 to -0.74) |
| Day 141: Dryness Score | -0.89 (-1.49 to -0.28) | -1.05 (-1.63 to -0.46) |
| Day 141: Fatigue Score | -1.18 (-1.83 to -0.53) | -1.73 (-2.36 to -1.11) |
| Day 141: Pain Score | -0.70 (-1.34 to -0.07) | -1.39 (-2.00 to -0.78) |
| Day 169: Dryness Score | -0.84 (-1.46 to -0.23) | -1.04 (-1.63 to -0.44) |
| Day 169: Fatigue Score | -1.28 (-1.93 to -0.64) | -1.57 (-2.19 to -0.95) |
| Day 169: Pain Score | -1.11 (-1.75 to -0.47) | -1.45 (-2.06 to -0.83) |
The Mean change from baseline in Schirmer's Test at all measured time points up to day 169 The length in millimeters that the strip wets during the 5 minute test period for each eye. Collection is done separately for each eye.
| millimeters | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 85: Study Eye | 1.9 (-0.0 to 3.9) | 1.5 (-0.5 to 3.5) |
| Day 85: Non-Study Eye | 0.1 (-2.0 to 2.2) | 0.8 (-1.2 to 2.9) |
| Day 85: Average of Both Eyes | 1.10 (-0.75 to 2.96) | 1.41 (-0.43 to 3.24) |
| Day 169: Study Eye | 1.7 (-0.4 to 3.9) | 1.0 (-1.1 to 3.2) |
| Day 169: Non-Study Eye | 0.6 (-1.3 to 2.4) | 0.2 (-1.7 to 2.1) |
| Day 169: Average of Both Eyes | 1.21 (-0.59 to 3.00) | 0.82 (-0.97 to 2.61) |
The Mean change from baseline in OSS at all measured time points up to day 169 Score of 0 = No Staining Score of 12 = diffuse staining The total score will be calculated as the sum of the score for these parameters for each eye. Medial Nasal Bulbar Conjunctiva (MNBC) \[score scale: 0 - 3\], Corneal (CORN) Staining of Punctate Epithelial Erosions (PEE) \[score scale: 0 - 3\], Lateral Temporal Bulbar Conjunctiva (LTBC) \[score scale: 0 - 3\], Patches of Confluent Staining (CONF) \[score scale: 0 - 1\], PEE observed in the pupil region, i.e. central 4mm diameter portion of the cornea (PUPL) \[score scale: 0 - 1\], one of more filaments seen anywhere on the cornea (FILA) \[score scale: 0 - 1\]
| Score on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 85: Study Eye | -1.7 (-2.5 to -0.9) | -0.5 (-1.3 to 0.3) |
| Day 85: Non-Study Eye | -0.6 (-1.4 to 0.2) | 0.4 (-0.4 to 1.2) |
| Day 85: Average of Both Eyes | -1.15 (-1.91 to -0.39) | -0.06 (-0.81 to 0.68) |
| Day 169: Study Eye | -1.5 (-2.3 to -0.6) | -0.7 (-1.6 to 0.1) |
| Day 169: Non-Study Eye | -0.5 (-1.3 to 0.3) | 0.3 (-0.5 to 1.2) |
| Day 169: Average of Both Eyes | -0.99 (-1.79 to -0.19) | -0.19 (-0.98 to 0.60) |
The Mean change from baseline in Tear Break-up Time at all measured time points up to day 169 The CRF collects the time in seconds to first appearance of a random dry spot on the corneal surface for 3 repetitions in each eye. The average time will calculated for each eye averaging the 3 measurements for each eye separately. In case only 2 measurements are available, the average of the 2 measurements will be calculated. In case there is only 1 measurement, that measurement will be used for the analysis.
| Seconds | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 85: Study Eye | -0.13 (-0.99 to 0.73) | 0.18 (-0.67 to 1.04) |
| Day 85: Non-Study Eye | -0.70 (-1.59 to 0.18) | -0.12 (-1.01 to 0.76) |
| Day 85: Average of Both Eyes | -0.41 (-1.24 to 0.43) | 0.09 (-0.74 to 0.92) |
| Day 169: Study Eye | -0.23 (-1.11 to 0.64) | -0.32 (-1.19 to 0.56) |
| Day 169: Non-Study Eye | -0.79 (-1.62 to 0.03) | -0.62 (-1.46 to 0.21) |
| Day 169: Average of Both Eyes | -0.50 (-1.32 to 0.31) | -0.43 (-1.25 to 0.39) |
The mean change from baseline in unstimulated whole salivary flow at all measured time points up to Day 169.
| mL/min | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 85 | 0.106 (-0.037 to 0.249) | 0.158 (0.022 to 0295) |
| Day 169 | 0.051 (-0.100 to 0.203) | 0.105 (-0.042 to 0.251) |
The mean change from baseline in Stimulated whole salivary flow at all measured time points up to Day 169.
| mL/min | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 85 | 0.11 (-0.039 to 0.262) | 0.169 (0.024 to 0.314) |
| Day 169 | 0.056 (-0.104 to 0.216) | 0.108 (-0.048 to 0.263) |
The mean change from baseline in participant symptoms using the Numeric Rating Scale (NRS) for mouth dryness at all measured time points up to Day 169. The oral and ocular dryness are each assessed by the patients with numeric rating scales from 0 to 10 with 0 representing no dryness and 10 representing maximal dryness
| Score on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | -0.8 (-8 to 3) | -0.5 (-7 to 6) |
| Day 57 | -1.3 (-8 to 5) | -0.9 (-7 to 6) |
| Day 85 | -1.3 (-9 to 4) | -1.1 (-6 to 8) |
| Day 113 | -1.2 (-9 to 3) | -1.3 (-8 to 4) |
| Day 141 | -1.3 (-8 to 5) | -1.1 (-6 to 6) |
| Day 169 | -1.3 (-8 to 3) | -1.2 (-6 to 8) |
The mean change from baseline in patient symptoms using the Numeric Rating Scale (NRS) for eye dryness at all measured time points up to Day 169. The oral and ocular dryness are each assessed by the patients with numeric rating scales from 0 to 10 with 0 representing no dryness and 10 representing maximal dryness
| Score on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | -0.4 (-8 to 5) | -0.3 (-6 to 5) |
| Day 57 | -0.9 (-7 to 5) | -0.6 (-6 to 5) |
| Day 85 | -0.9 (-7 to 6) | -0.8 (-7 to 8) |
| Day 113 | -1.0 (-7 to 7) | -1.1 (-8 to 4) |
| Day 141 | -0.8 (-7 to 7) | -1.0 (-7 to 4) |
| Day 169 | -0.9 (-5 to 6) | -1.0 (-7 to 5) |
The participant global assessment of disease activity are assessed with visual analog scales. The participant marks a vertical line through a horizontal line, where the beginning of the horizontal line represents the best situation, and the end of the horizontal line represents the very worst situation. The CRF collects the distance in millimeters from the start of the scale that is marked as well as the length of the scale in millimeters. In cases that the length of the scale is in less or more than 100 millimeters, then the participants measurement will be rescaled to the equivalent of 100 millimeters using the formula below: Rescale Measurement in mm = (measurement as reported on CRF in mm/length of the line on CRF in mm) \* 100mm A negative score = participant assessment of disease activity has improved A positive score = participant assessment of disease activity has worsened
| Score on VAS 0-100mm scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | -4.0 (-9.8 to 1.7) | -7.1 (-12.7 to -1.4) |
| Day 57 | -7.5 (-13.4 to -1.7) | -6.3 (-11.9 to -0.6) |
| Day 85 | -10.4 (-16.3 to -4.4) | -10.2 (-16.0 to -4.4) |
| Day 113 | -8.0 (-14.0 to -2.0) | -9.7 (-15.5 to -3.9) |
| Day 141 | -5.1 (-11.0 to 0.8) | -11.0 (-16.7 to -5.3) |
| Day 169 | -10.1 (-16.1 to -4.0) | -9.0 (-14.8 to -3.1) |
The physician global assessment of disease activity are assessed with visual analog scales. The physician marks a vertical line through a horizontal line, where the beginning of the horizontal line represents the best situation, and the end of the horizontal line represents the very worst situation. The CRF collects the distance in millimeters from the start of the scale that is marked as well as the length of the scale in millimeters. In cases that the length of the scale is in less or more than 100 millimeters, then the participants measurement will be rescaled to the equivalent of 100 millimeters using the formula below: Rescale Measurement in mm = (measurement as reported on CRF in mm/length of the line on CRF in mm) \* 100mm A negative score = physician assessment of disease activity has improved A positive score = physician assessment of disease activity has worsened
| Score on VAS 0-100mm Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | -10.3 (-14.8 to -5.8) | -10.5 (-14.9 to -6.1) |
| Day 57 | -16.2 (-20.8 to -11.7) | -16.7 (-21.1 to -12.3) |
| Day 85 | -20.8 (-25.6 to -16.0) | -19.4 (-24.0 to -14.7) |
| Day 113 | -22.8 (-27.9 to -17.8) | -19.8 (-24.6 to -14.9) |
| Day 141 | -23.7 (-28.6 to -18.8) | -21.7 (-26.5 to -17.0) |
| Day 169 | -23.0 (-27.8 to -18.2) | -23.7 (-28.3 to -19.0) |
The mean change from baseline in patient fatigue using Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue assessment of disease activity at all measured time points up to Day 169. PROMIS Fatigue instruments 10 Questions ranging from a score 0 to 40. Sum of the values gives you the raw sum. The raw is inputted into this formula to give you the raw score: Raw Score = (Raw sum\*number of items on the short form)/(Number of items that were actually answered) Raw score is translated to a T-Score using a table. T-Score is used as the final score. The T-score rescales the raw score into a standardized score with a mean of 50 and a standard deviation (SD) of 10. The standardized T-score is reported as the final score for each participant. A negative T Score = Better Prognosis A positive T Score = Worse prognosis
| T-Score | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | -3.08 (-5.22 to -0.95) | -3.99 (-6.09 to -1.88) |
| Day 57 | -4.12 (-6.27 to -1.97) | -4.02 (-6.12 to -1.91) |
| Day 85 | -4.85 (-7.05 to -2.64) | -5.48 (-7.64 to -3.32) |
| Day 113 | -4.17 (-6.37 to -1.97) | -5.32 (-7.48 to -3.17) |
| Day 141 | -4.84 (-7.06 to -2.62) | -5.68 (-7.85 to -3.52) |
| Day 169 | -5.56 (-7.83 to -3.28) | -5.59 (-7.82 to -3.37) |
For the FSFI, is a 19 item instrument used for assessing key dimensions of female sexual function over the past 4 weeks with 6 domains being analyzed. The specific domains (desire, arousal, lubrication, orgasm, satisfaction, and pain) analyzed in the FSFI are scored on a scale ranging from 0 to 5, with higher scores indicating better performance. Domain scores are calculated by summing the scores of the individual questions that make up the domain and multiplying the sum by the factor in the table below. The full scale score is the sum of the six domain scores. Full Scale Score range: 2.0(minimum score) - 36.0 (maximum score) Negative Score = Reduced functioning Positive Score = Improved functioning
| Scores on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 85 | -2.44 (-5.67 to 0.78) | -1.56 (-4.90 to 1.77) |
| Day 169 | -2.32 (-5.73 to 1.09) | -1.87 (-5.42 to 1.68) |
The SF-36 determines participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Scores on each item are summed and averaged (range: 0=worst to 100=best). Increases from baseline indicate improvement
| Score on a Scale | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 85: Physical Function | 1.908 (-0.240 to 4.056) | 1.523 (-0.568 to 3.614) |
| Day 85: Role Physical | 5.248 (3.112 to 7.383) | 4.416 (2.321 to 6.511) |
| Day 85: Bodily Pain | 3.200 (0.910 to 5.490) | 3.721 (1.464 to 5.978) |
| Day 85: General Health | 4.042 (1.938 to 6.146) | 3.409 (1.363 to 5.456) |
| Day 85: Vitality | 3.827 (1.269 to 6.384) | 3.859 (1.335 to 6.382) |
| Day 85: Social Functioning | 3.020 (0.296 to 5.744) | 4.771 (2.117 to 7.426) |
| Day 85: Role-Emotional | 3.024 (0.214 to 5.834) | 4.834 (2.093 to 7.576) |
| Day 85: Mental Health | 2.942 (0.458 to 5.425) | 2.287 (-0.135 to 4.709) |
| Day 85: Physical component Summary | 3.430 (1.615 to 5.244) | 2.686 (0.904 to 4.468) |
| Day 85: Mental component Summary | 2.693 (0.160 to 5.226) | 3.672 (1.208 to 6.136) |
| Day 169: Physical Function | 2.927 (0.593 to 5.261) | 1.742 (-0.505 to 3.989) |
| Day 169: Role-Physical | 5.853 (3.756 to 7.949) | 4.626 (2.604 to 6.649) |
| Day 169: Bodily Pain | 3.842 (1.432 to 6.252) | 3.458 (1.114 to 5.801) |
| Day 169: General Health | 3.880 (1.700 to 6.060) | 3.764 (1.665 to 5.862) |
| Day 169: Vitality | 3.742 (1.160 to 6.324) | 4.523 (2.005 to 7.041) |
| Day 169: Social functioning | 4.125 (1.320 to 6.929) | 4.471 (1.773 to 7.169) |
| Day 169: Role-Emotional | 4.653 (1.943 to 7.364) | 4.930 (2.334 to 7.526) |
| Day 169: Mental Health | 2.375 (-0.116 to 4.866) | 2.972 (0.581 to 5.363) |
| Day 169: Physical Component Summary | 3.998 (2.045 to 5.951) | 2.650 (0.756 to 4.543) |
| Day 169: Mental Component Summary | 2.940 (0.368 to 5.512) | 4.112 (1.648 to 6.577) |
Geometric mean of trough concentration (Cmin) of abatacept at all measured time points.
| µg/mL | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Day 29 | 21.401 ± 36 | — |
| Day 85 | 27.543 ± 38.4 | — |
| Day 113 | 25.567 ± 42.1 | — |
| Day 141 | 25.870 ± 40.8 | — |
| Day 169 | 24.522 ± 42.7 | — |
Percentage of participants with at least one positive immunogenicity response up to Day 169 and during 3 months follow up (for participants who discontinue during the 6-months double-blind).
| Percentage | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Study Day 169 | 1.2 | — |
| Post Treatment Day 85 (DB) | 0 | — |
| Post Treatment Day 169 (DB) | 0 | — |
Percentage of participants with adverse events, deaths, serious adverse events and adverse events leading to discontinuation
| Percentage | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Adverse Events (AEs) | 85.9 | 71.6 |
| Deaths | 0 | 1.1 |
| Serious Adverse Events | 9.8 | 3.2 |
| Discontinuation due to AEs | 3.3 | 2.1 |
Laboratory values meeting the marked abnormality criteria
| Percentage | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period |
|---|---|---|
| Hematocrit High | NA | NA |
| Hematocrit Low | 0 | 0 |
| Hemoglobin High | NA | NA |
| Hemoglobin Low | 0 | 0 |
| Platelet count High | 0 | 0 |
| Platelet count low | 0 | 0 |
| Leukocytes high | 1.1 | 0 |
| Leukocytes low | 12.1 | 8.4 |
| Basophils high | 0 | 0 |
| Basophils Low | NA | NA |
| Eosinophils High | 4.4 | 1.1 |
| Eosinophils Low | NA | NA |
| lymphocytes high | 0 | 0 |
| lymphocytes low | 9.9 | 14.7 |
| Monocytes high | 0 | 0 |
| Monocytes Low | NA | NA |
| Neutrophils+Bands High | NA | NA |
| Neutrophils+Bands Low | 6.6 | 1.1 |
| Alanine Aminotransferase High | 1.1 | 2.1 |
| Alkaline Phosphatase HIgh | 0 | 0 |
| Aspartate Aminotransferase High | 1.1 | 3.2 |
| Bilirubin, Total High | 0 | 0 |
| G-Glutamyl Transferase High | 6.6 | 1.1 |
| Blood Urea Nitrogen High | 1.1 | 1.1 |
| Creatinine High | 0 | 0 |
| Calcium High | 0 | 0 |
| Calcium Low | 1.1 | 0 |
| Chloride High | 0 | 0 |
| Chloride Low | 1.1 | 0 |
| Phosphorus High | 0 | 0 |
| Phosphorus Low | 0 | 1.1 |
| Potassium High | 0 | 0 |
| Potassium Low | 1.1 | 0 |
| Sodium High | 0 | 1.1 |
| Sodium Low | 2.2 | 0 |
| Glucose, Serum High | 0 | 1.1 |
| Glucose, Serum Low | 2.2 | 5.3 |
| Albumin High | NA | NA |
| Albumin Low | 2.2 | 1.1 |
| Protein, Total High | 2.2 | 3.2 |
| Protein, Total Low | 1.1 | 0 |
| Creatine Kinase High | 0 | 4.2 |
| Blood, Urine High | 14.3 | 9.5 |
| Blood, Urine Low | NA | NA |
| Glucose, Urine High | 0 | 0 |
| Glucose, Urine Low | NA | NA |
| Protein, Urine High | 2.2 | 3.2 |
Percentage of participants with at least one positive immunogenicity response On Day 365 (end of Open label treatment period) and day 85 post open label follow up period.
| Percentage | Abatacept - Cumulative Open Label Treatment Period |
|---|---|
| Study Day 365 | 2.1 |
| Post Treatment Day 85 (OL) | 43.2 |
Percentage of participants with adverse events, deaths, serious adverse events and adverse events leading to discontinuation
| Percentage | Cumulative Treatment Period |
|---|---|
| Adverse Events (AEs) | 78.7 |
| Deaths | 0.6 |
| Serious Adverse Events (SAEs) | 14.6 |
| Discontinuation due to AEs | 5.6 |
| Related Serious Adverse Events | 3.4 |
| Discontinued due to SAEs | 3.4 |
| Related AEs | 40.4 |
Laboratory values meeting the marked abnormality criteria
| Percentage | Cumulative Open Label Treatment Period |
|---|---|
| Hematocrit High | NA |
| Hematocrit Low | 0 |
| Hemoglobin High | NA |
| Hemoglobin Low | 0.6 |
| Platelet count High | 0 |
| Platelet count low | 0.6 |
| Leukocytes high | 0.6 |
| Leukocytes low | 18.6 |
| Basophils high | 0.6 |
| Basophils Low | NA |
| Eosinophils High | 5.6 |
| Eosinophils Low | NA |
| lymphocytes high | 0 |
| lymphocytes low | 12.4 |
| Monocytes high | 0 |
| Monocytes Low | NA |
| Neutrophils+Bands High | NA |
| Neutrophils+Bands Low | 7.3 |
| Alanine Aminotransferase High | 1.7 |
| Alkaline Phosphatase HIgh | 0.6 |
| Aspartate Aminotransferase High | 1.1 |
| Bilirubin, Total High | 0 |
| G-Glutamyl Transferase High | 5.6 |
| Blood Urea Nitrogen High | 1.7 |
| Creatinine High | 0.6 |
| Calcium High | 0 |
| Calcium Low | 1.1 |
| Chloride High | 0 |
| Chloride Low | 1.1 |
| Phosphorus High | 0.6 |
| Phosphorus Low | 1.1 |
| Potassium High | 0.6 |
| Potassium Low | 0.6 |
| Sodium High | 0.6 |
| Sodium Low | 1.7 |
| Glucose, Serum High | 0.6 |
| Glucose, Serum Low | 5.1 |
| Albumin High | NA |
| Albumin Low | 1.7 |
| Protein, Total High | 4.0 |
| Protein, Total Low | 0.6 |
| Creatine Kinase High | 2.3 |
| Blood, Urine High | 14.7 |
| Blood, Urine Low | NA |
| Glucose, Urine High | 0 |
| Glucose, Urine Low | NA |
| Protein, Urine High | 5.6 |
| WBC, Urine High | 100.0 |
Collected over First dose to 169 days past open label period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept - Double Blind Treatment Period | 0/92 (0%) | 9/92 (9.8%) | 47/92 (51.1%) |
| Placebo - Double Blind Treatment Period | 1/95 (1.1%) | 3/95 (3.2%) | 40/95 (42.1%) |
| Abatacept - Open Label Treatment Period | 1/178 (0.6%) | 19/178 (10.7%) | 61/165 (37%) |
| Event | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period | Abatacept - Open Label Treatment Period |
|---|---|---|---|
| Device dislocationProduct Issues | 0/92 | 0/95 | 2/165 |
| Prinzmetal anginaCardiac disorders | 1/92 | 0/95 | 0/165 |
| Intestinal obstructionGastrointestinal disorders | 1/92 | 0/95 | 0/165 |
| Hepatic cyst rupturedHepatobiliary disorders | 1/92 | 0/95 | 0/165 |
| Anaphylactoid reactionImmune system disorders | 1/92 | 0/95 | 0/165 |
| Drug hypersensitivityImmune system disorders | 1/92 | 0/95 | 0/165 |
| Pneumonia bacterialInfections and infestations | 1/92 | 0/95 | 0/165 |
| ArthropathyMusculoskeletal and connective tissue disorders | 1/92 | 0/95 | 0/165 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/92 | 0/95 | 0/165 |
| Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/92 | 0/95 | 0/165 |
| Event | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period | Abatacept - Open Label Treatment Period |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 11/92 | 18/95 | 22/165 |
| DiarrhoeaGastrointestinal disorders | 11/92 | 4/95 | 9/165 |
| HeadacheNervous system disorders | 10/92 | 9/95 | 9/165 |
| NauseaGastrointestinal disorders | 9/92 | 4/95 | 1/165 |
| Upper respiratory tract infectionInfections and infestations | 9/92 | 7/95 | 15/165 |
| Urinary tract infectionInfections and infestations | 6/92 | 8/95 | 12/165 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 6/92 | 1/95 | 2/165 |
| Abdominal pain upperGastrointestinal disorders | 5/92 | 0/95 | 4/165 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/92 | 2/95 | 4/165 |
| InsomniaPsychiatric disorders | 5/92 | 1/95 | 2/165 |
| Age, Continuous(Years) | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period | Total |
|---|---|---|---|
| Mean | 51.2 ± 12.3 | 52.9 ± 13.5 | 52.0 ± 12.9 |
| Age, Customized(Participants) | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period | Total |
|---|---|---|---|
| < 65 years | 80 | 73 | 153 |
| ≥ 65 years | 12 | 22 | 34 |
| ≤ 50 years | 42 | 42 | 84 |
| > 50 years | 50 | 53 | 103 |
| Sex: Female, Male(Participants) | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period | Total |
|---|---|---|---|
| Female | 85 | 92 | 177 |
| Male | 7 | 3 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 7 |
| Not Hispanic or Latino | 10 | 13 | 23 |
| Unknown or Not Reported | 80 | 77 | 157 |
| Race (NIH/OMB)(Participants) | Abatacept - Double Blind Treatment Period | Placebo - Double Blind Treatment Period | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 21 | 23 | 44 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 10 | 9 | 19 |
| White | 60 | 60 | 120 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Aug 2018, 20 months.
Results were first posted in Jan 2020, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept